ENANTA PHARMACEUTICALS INC

Listed Company

ENTACIK 0001177648NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsFY ends Sep 30

Period

FY 2025

Revenue

$65.32M

Net Income

$-81.89M

Total Assets

$280.73M

Equity

$64.72M

Shares Out

29.08M

Op. Cash Flow

$-19.27M

ENTA$13.74+89.78% · past yearDBEQ Basic

Daily closing prices

Business

Enanta Pharmaceuticals is a biotechnology company that discovers and develops small-molecule drugs for virology and immunology indications using its chemistry-driven approach. The company's marketed product is glecaprevir, a protease inhibitor co-formulated in AbbVie's MAVYRET/MAVIRET for hepatitis C, generating royalty revenue. Current development programs include clinical-stage RSV candidates (zelicapavir and EDP-323), preclinical immunology programs targeting KIT and STAT6 for inflammatory diseases, and earlier-stage programs in SARS-CoV-2 and hepatitis B. The company operates in the United States and international markets.

Summary from 10-K filed 2025-11-19

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Total revenue	65	68	79	86	97
Research and development	107	131	164	165	174
General and administrative	44	58	53	45	33
Total operating expenses	151	189	216	210	207
Loss from operations	−85	−122	−137	−124	−110
Interest expense	−8	−11	−5	0	—
Interest and investment income, net	9	15	11	2	—
Change in fair value of Series 1 nonconvertible preferred stock	39,000	73,000	0	83,000	−27,000
Total other income, net	2	4	6	2	2
Loss before income taxes	−84	−118	−131	−122	−108
Income tax benefit (expense)	2	2	−3	433,000	29
Net loss	−82	−116	−134	−122	−79
Basic (per share)	−3.84	−5.48	−6.38	−5.91	−3.92
Diluted (per share)	−3.84	−5.48	−6.38	−5.91	−3.92
Basic (shares)	21,336	21,157	20,969	20,603	20,171
Diluted (shares)	21,336	21,157	20,969	20,603	20,171

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Cash and cash equivalents	32	37	85	44	57
Short-term marketable securities	157	211	285	205	187
Accounts receivable	7	7	9	20	24
Prepaid expenses and other current assets	9	12	13	13	14
Income tax receivable	0	32	31	29	37
Short-term restricted cash	0	608,000	0	—	—
Total current assets	204	300	423	312	319
Property and equipment, net	35	33	12	6	6
Operating lease, right-of-use assets	38	41	23	24	5
Long-term restricted cash	3	3	4	—	—
Other long-term assets	92,000	94,000	803,000	696,000	92,000
Total assets	281	377	462	375	439
Accounts payable	2	8	4	6	10
Accrued expenses and other current liabilities	13	14	18	21	22
Liability related to the sale of future royalties	31	34	35	0	—
Operating lease liabilities	3	2	5	3	4
Total current liabilities	49	58	63	30	36
Liability related to the sale of future royalties, net of current portion	111	135	159	0	—
Operating lease liabilities, net of current portion	55	54	21	22	1
Series 1 nonconvertible preferred stock	1	1	1	1	2
Other long-term liabilities	260,000	231,000	663,000	454,000	558,000
Total liabilities	216	248	246	54	39
Commitments and contingencies (Note 13)	—	—	—	—	—
Common stock; $0.01 par value per share, 100,000 shares authorized; 21,387 and 21,194 shares issued and outstanding at September 30, 2025 and September 30, 2024, respectively	214,000	212,000	211,000	208,000	202,000
Additional paid-in capital	470	451	425	398	351
Accumulated other comprehensive (loss) gain	−339,000	302,000	−1	−4	−382,000
Accumulated deficit	−405	−323	−207	−73	49
Total stockholders' equity	65	129	217	321	399
Total liabilities and stockholders' equity	281	377	462	375	439

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Net loss	−82	−116	−134	−122	−79
Stock-based compensation expense	19	27	28	27	21
Depreciation and amortization expense	5	2	2	3	3
Non-cash interest associated with the sale of future royalties	−630,000	−135,000	5	0	0
Non-cash royalty revenue	−283,000	2	−10	0	0
Premium paid on marketable securities	0	0	−73,000	−846,000	−4
Amortization (accretion) of premiums (discounts) on marketable securities	503,000	−1	−3	1	2
Loss on disposal of property and equipment	6,000	16,000	150,000	0	0
Accounts receivable	−236,000	2	12	3	−84,000
Prepaid expenses and other current assets	4	850,000	182,000	743,000	−533,000
Income tax receivable	32	−995,000	−2	9	−24
Operating lease, right-of-use assets	4	6	5	5	5
Other long-term assets	2,000	709,000	−107,000	−604,000	0
Accounts payable	−1	−414,000	−1	−5	4
Accrued expenses	58,000	−6	−3	−1	8
Operating lease liabilities	1	5	−3	−4	−6
Other long-term liabilities	29,000	−432,000	209,000	−104,000	−520,000
Net cash used in operating activities	−19	−79	−103	−85	−70
Purchase of marketable securities	−210	−307	−373	−171	−307
Proceeds from maturities and sale of marketable securities	263	383	329	228	345
Purchase of property and equipment	−13	−18	−9	−2	−750,000
Net cash provided by (used in) investing activities	40	58	−54	55	37
Payments on royalty sale liability, net of imputed interest	−26	−27	0	0	—
Proceeds from the exercise of stock options	145,000	147,000	2	21	4
Proceeds from the sale of future royalties	0	0	200	0	0
Payments for debt issuance costs	0	0	−325,000	0	0
Payments for settlement of share-based awards	−277,000	−294,000	−4	−1	−534,000
Net cash (used in) provided by financing activities	−27	−28	198	20	3
Net (decrease) increase in cash, cash equivalents and restricted cash	−6	−48	41	−10	−30
Cash paid for taxes	109,000	241,000	5	0	32,000
Cash paid for interest	9	12	2	0	—
Cash received from tenant improvement allowances	6	9	2	0	—
Cash received from income tax refund	34	0	0	—	—
Purchases of fixed assets included in accounts payable and accrued expenses	0	6	424,000	1	137,000
Operating lease liabilities arising from obtaining right-of-use assets	1	24	4	24	3

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is ENANTA PHARMACEUTICALS INC's CIK number?

ENANTA PHARMACEUTICALS INC's SEC CIK number is 0001177648 (1177648). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find ENANTA PHARMACEUTICALS INC's SEC filings?

All of ENANTA PHARMACEUTICALS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did ENANTA PHARMACEUTICALS INC last report earnings?

ENANTA PHARMACEUTICALS INC (ENTA) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-216735). This is ENANTA PHARMACEUTICALS INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is ENANTA PHARMACEUTICALS INC's most recent earnings 8-K?

ENANTA PHARMACEUTICALS INC's latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001193125-26-216735. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View ENANTA PHARMACEUTICALS INC's latest earnings 8-K →
Look up any company's CIK number →